BridgeBio Pharma, Inc. — Director's Dealing 2025

Dec 8, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2025-12-04

Reporting Person: Kumar Neil (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-12-04	Common Stock	S	2100	$73.1611	Disposed	793586	Indirect
2025-12-04	Common Stock	S	12192	$74.4243	Disposed	781394	Indirect
2025-12-04	Common Stock	S	5708	$74.7966	Disposed	775686	Indirect
2025-12-05	Common Stock	S	12517	$73.0466	Disposed	763169	Indirect
2025-12-05	Common Stock	S	7483	$73.7607	Disposed	755686	Indirect
2025-12-04	Common Stock	S	2100	$73.1554	Disposed	4596347	Indirect
2025-12-04	Common Stock	S	12200	$74.4238	Disposed	4584147	Indirect
2025-12-04	Common Stock	S	5700	$74.7996	Disposed	4578447	Indirect
2025-12-05	Common Stock	S	12288	$73.0411	Disposed	4566159	Indirect
2025-12-05	Common Stock	S	7712	$73.7498	Disposed	4558447	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	228776	Direct

Footnotes

F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on March 31, 2025.

F2: Represents the weighted average sale price of the shares sold from $72.71 to $73.70 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

F3: The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.

F4: Represents the weighted average sale price of the shares sold from $73.73 to $74.72 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

F5: Represents the weighted average sale price of the shares sold from $74.73 to $74.94 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

F6: Represents the weighted average sale price of the shares sold from $72.46 to $73.45 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

F7: Represents the weighted average sale price of the shares sold from $73.46 to $74.23 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

F8: Represents the weighted average sale price of the shares sold from $72.71 to $73.66 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

F9: Represents the weighted average sale price of the shares sold from $72.41 to $73.40 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

F10: Represents the weighted average sale price of the shares sold from $73.42 to $74.23 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.